§ 参考文献
1.Roche presents the first Phase I efficacy and safety data on CEA-TCB(CEA CD3 TCB),a novel T-cell bispecific antibody targeting solid tumours,http://www.roche.com/investors/updates/inv-update-2017-05-18.html。
2.A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody(CEA TCB)for the Treatment of Solid Tumors.Clin Cancer Res;22(13)July 1,2016。
(生物谷Bioon)